WILEX AG successfully completes capital reduction

PDF Download


Munich, 15 July 2014 – WILEX AG (ISIN DE0006614720 / WL6 / FSE) today announced that the capital reduction resolved by the Annual General Meeting on 23 May 2014 has been implemented in a 4:1 ratio according to plan. The entry of the capital reduction in the commercial register on 09 July 2014 reduced the number of outstanding no par value shares by 23,456,628 to 7,818,876 through consolidation of the shares in the ratio of 4:1. Prior to this, as also resolved by the Annual General Meeting, the company’s share capital had been reduced by three shares from 31,275,507 to 31,275,504 to obtain an even reduction ratio for the ordinary capital reduction.

This measure does not affect the percentage shareholdings of the individual shareholders of WILEX AG. However, starting on 18 July 2014 the converted WILEX shares will be traded on stock exchanges under the new international securities identification number ISIN DE000A11QVV0, ticker symbol WL6.

As a result of the reverse split, the share capital of WILEX AG will be reduced by EUR 23,456,628.00 to EUR 7,818,876.00. The difference of EUR 23,456,628.00 will be reclassified on the liabilities side of the balance sheet of WILEX AG from subscribed capital to capital reserves. Equity and total assets remain unchanged.

A fractional rights regulation is planned for shareholders whose number of shares is not divisible by four on the evening of 17 July 2014. Shareholders can decide individually whether they wish to purchase or surrender 0.25 to 0.75 fractional rights of WILEX under the fractional rights regulation. For this, shareholders will receive an instruction form from their custodian bank after 18 July 2014. If shareholders do not instruct their custodian bank to round their shareholdings up or down, the share fractions in question will be automatically sold and the proceeds credited to the corresponding shareholders.

WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused on oncology, the Company’s portfolio includes diagnostic and therapeutic product candidates for the specific detection and targeted treatment of various types of cancer based on antibodies and small molecules. Our aim is out-licensing these clinical projects. The Wilex subsidiary Heidelberg Pharma GmbH in Ladenburg, Germany, offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform. More information is available at www.wilex.com.

Company contact
Sylvia Wimmer
Tel.: +49 (0)89-41 31 38-29
Email: investors[at]wilex.com
Grillparzerstr. 10, 81675 Munich, Germany 
IR/PR support
MC Services AG
Katja Arnold (CIRO)
Executive Director
Tel.: +49-89-210 228-40
Email: katja.arnold[at]mc-services.eu 

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Seite gelesen: 430 | Heute: 2